EUVIMEDEUVIMED entdecken
Open Access

Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials

Brian J Werth iD, Rutan Zhang, Ismael A Barreras Beltran, Kelsi Penewit, Adam Waalkes, Elizabeth A Holmes, Stephen J Salipante, Libin Xu iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Brian J Werth und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Pharmacy, University of Washington, 1959 NE Pacific St., HSB H-375, Box 357630, Seattle, WA 98195-7630, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus, Glycopeptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, Cystic Fibrosis Foundation, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dalbavancin exposures select for VAN and daptomycin cross-resistance in Staphylococcus aureus often by walK-related mutations. Oritavancin is another long-acting lipoglycopeptide, but its proclivity to select for cross-resistance is unknown. The objective of this study was to determine if post-distributional pharmacokinetic oritavancin exposures select for meaningful susceptibility changes in S. aureus.

Methods

We simulated average post-distributional, free-drug exposures of oritavancin 1200 mg IV once (fCmax 11.2 µg/mL; β-elimination t1/2 13.4 h; γ-elimination t1/2 245 h) in an in vitro pharmacodynamic model for 28 days against five S. aureus including four MRSA. Samples were taken daily for colony enumeration and resistance screening. Susceptibility testing was repeated on isolates from resistance screening plates against oritavancin, vancomycin, daptomycin, dalbavancin and 6 beta-lactams with varying penicillin-binding protein affinities.

Results

Tested oritavancin exposures were bactericidal against 5/5 strains for 2–17 days before regrowth of less-susceptible subpopulations occurred. Isolates with reduced susceptibility to oritavancin were detected as early as 5 days, but the MIC increased above the susceptibility breakpoint (>0.125 mg/L) in 4/5 strains eventually. Vancomycin and daptomycin MICs increased by 2- to 8-fold but did not exceed the susceptibility breakpoints in most isolates. β-lactam MICs were largely unchanged among the recovered isolates with reduced oritavancin susceptibility. Mutations were diverse but often involved purR with 13 unique variants identified among 4/5 strains.

Conclusions

Oritavancin-selected resistance was primarily associated with purR mutation and less frequently associated with cross-resistance and walK mutation than dalbavancin-selected resistance in similar strains and conditions. The reason for this is unclear but may stem from differences in the mechanism(s) and divergent mutational pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusGlycopeptidesLipoglycopeptidesMicrobial Sensitivity TestsHumansColony Count, MicrobialDrug Resistance, BacterialDaptomycinVancomycin

Substanzen

oritavancinLipoglycopeptidesAnti-Bacterial AgentsGlycopeptidesDaptomycinVancomycin

Autor:innen und Institutionen

  • Department of Pharmacy, School of Pharmacy, University of Washington, 1959 NE Pacific St., HSB H-375, Box 357630, Seattle, WA 98195-7630, USA.
  • Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA, USA.
  • Department of Laboratory Medicine, School of Pharmacy, University of Washington, Seattle, WA, USA.

ORCID-Profile: Brian J Werth, Libin Xu

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Cystic Fibrosis Foundation
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Werth, B. J., Zhang, R., Barreras Beltran, I. A., Penewit, K., Waalkes, A., Holmes, E. A., Salipante, S. J., & Xu, L. (2025). Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf042

Vancouver

Werth BJ, Zhang R, Barreras Beltran IA, Penewit K, Waalkes A, Holmes EA, et al. Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf042

BibTeX
@article{Werth2025,
  author = {Werth, Brian J and Zhang, Rutan and Barreras Beltran, Ismael A and Penewit, Kelsi and Waalkes, Adam and Holmes, Elizabeth A and Salipante, Stephen J and Xu, Libin},
  title = {Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf042}
}
Kostenlos starten →